Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02408042

Study Title
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)(NCT02408042)

Trial Description
To determine the recommended phase 2 dose of chemotherapy in combination with pembrolizumab (formerly MK-3475 and lambrolizumabKeytruda®/Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) in subjects with advanced lymphoma and determine the complete response rate. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

This trial is sponsored by Western Regional Medical Center. [1]

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar